Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Trevi Therapeutics Inc (TRVI)

215 + Investors. Track Smart Money conviction in TRVI. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +20
Streak
8Q ▲
Buyers last Q
61%

Smart Money Signals — TRVI

Based on 217 hedge funds · latest filing: 2026 Q2 · updated quarterly

📈

Buying streak — 8 quarters in a row

last 6Q
For 8 consecutive quarters, more hedge funds added TRVI than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
217 hedge funds hold TRVI right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +40% more funds vs a year ago

fund count last 6Q
+62 new funds entered over the past year (+40% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟢

More buyers than sellers — 61% buying

133 buying86 selling
Last quarter: 133 funds were net buyers (45 opened a brand new position + 88 added to an existing one). Only 86 were sellers (61 trimmed + 25 sold completely). A clear majority buying is a strong confirmation signal.
➡️

Steady new buyers — ~45 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 34 → 33 → 41 → 45. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
📌

Mixed — 28% long-term, 35% new

■ 28% conviction (2yr+) ■ 37% medium ■ 35% new
Of the 217 current holders: 61 (28%) held >2 years, 81 held 1–2 years, and 75 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.
💰

Value +71% but shares only +11% — price-driven

Value
+71%
Shares
+10%
Last quarter: the total dollar value of institutional holdings rose +71%, but actual share count only changed +11%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
📈

Growing discovery — still being found

38 → 34 → 33 → 41 → 45 new funds/Q
New funds entering each quarter: 34 → 33 → 41 → 45. A growing number of institutions are discovering TRVI each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.
📊

Mixed cohorts — 32% veterans, 47% new entrants

■ 32% veterans ■ 21% 1-2yr ■ 47% new
Of 220 current holders: 71 (32%) held 2+ years, 46 held 1–2 years, 103 (47%) entered in the past year. Balanced distribution — some institutional memory, some recent momentum buyers.
✅

Strong quality — 32% AUM from major funds

32% from top-100 AUM funds
42 of 215 holders rank in the top 100 by AUM, accounting for 32% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
4.3
out of 10
Moderate Exit Risk
Exit risk score 4.3/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — TRVI

In 2026 Q2, 133 hedge funds were net buyers of TRVI (45 opened a new position, 88 added to an existing one), while 86 reduced or exited (61 trimmed, 25 sold completely) — a 61% buyer ratio, indicating clear institutional accumulation. This marks 8 consecutive quarters of net institutional buying — a persistent conviction signal. 32% of total institutional value in TRVI is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: +20 funds (more new holders than closures). Total institutional holders: 217.

Hedge Fund Ownership: TRVI

How many hedge funds hold TRVI — quarterly history vs. share price
Quarterly hedge fund ownership of TRVI vs. share price

Market Analysis: TRVI

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: TRVI

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Trevi Therapeutics Inc (TRVI) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much TRVI has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 50d ago
TRVI
-0.1%
XLV
+10.0%

TRVI outperformed XLV by -10.1% since June 30, 2026.

Since 13F Filing Date August 14, 2026 · 5d ago
TRVI
+0.9%
XLV
+4.3%

Since the filing became public, TRVI outperformed XLV by -3.4% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

13 top-rated funds 8 high-conviction
Consensus
5.0
/ 10
breadth
×
Elite
5.7
/ 10
conviction
Hedge Fund Positioning: TRVI
215 + Investors

Track Smart Money conviction in TRVI. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q2) Prior (2026 Q1) Change
Funds Holding 215 197 9.14%
13F Shares 150M 136M 10.56%
Total Value $2.78B $1.63B 71.12%
New Positions 45 41 +4
Increased Positions 85 64 +21
Closed Positions 25 25 -
Reduced Positions 60 62 -2
Total Calls 4 5 -20.0%
Total Puts 1 3 -66.67%
PUT/CALL Ratio 0.25 0.6 Bullish

Statistics: TRVI

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

215 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in TRVI. Verified SEC 13F-HR filings.

QUARTER:
Top 25 TRVI holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 NEA Management Company, LLC 15.53% 13,222,228 $246.6M
2 Acorn Capital Advisors, LLC 10.92% 2,144,844 $40.0M
3 Pivotal bioVenture Partners Investment Advisor LLC 10.56% 1,742,672 $32.5M
4 Vivo Capital, LLC 8.68% 5,094,668 $95.0M
5 Artia Global Partners LP 7.61% 2,210,852 $41.2M
6 Superstring Capital Management LP 6.17% 524,224 $9.8M
7 KVP Capital Advisors, LP 5.67% 414,000 $7.7M
8 Jones Hill Capital LP 5.31% 1,339,212 $25.0M
9 Frazier Life Sciences Management, L.P. 4.04% 9,939,447 $185.4M
10 MPM BioImpact LLC 3.50% 3,073,577 $57.3M
11 Saturn V Capital Management LP 2.81% 1,052,043 $19.6M
12 First Light Asset Management, LLC 2.38% 2,097,215 $39.1M
13 NAN FUNG TRINITY (HK) Ltd 2.23% 1,213,620 $22.6M
14 Affinity Asset Advisors, LLC 1.52% 1,800,172 $33.6M
15 Logos Global Management LP 1.51% 1,880,000 $35.1M
16 Vestal Point Capital, LP 1.35% 3,100,000 $57.8M
17 Silverarc Capital Management, LLC 1.31% 678,095 $12.6M
18 Sphera Funds Management LTD. 1.21% 499,029 $9.3M
19 Sectoral Asset Management Inc 0.85% 65,596 $1.2M
20 Emerald Mutual Fund Advisers Trust 0.79% 1,210,965 $22.6M
21 Emerald Advisers, LLC 0.79% 1,797,611 $33.5M
22 Soleus Capital Management, L.P. 0.76% 1,179,618 $22.0M
23 Siren, L.L.C. 0.67% 1,786,867 $33.3M
24 Eventide Asset Management, LLC 0.66% 2,660,000 $49.6M
25 PFS Partners, LLC 0.60% 79,000 $1.5M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Trevi Therapeutics Inc (TRVI)

What does the Smart Money Trend signal show for TRVI?

Buying streak — 8 quarters in a row: For 8 consecutive quarters, more hedge funds added TRVI than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for TRVI?

More buyers than sellers — 61% buying: Last quarter: 133 funds were net buyers (45 opened a brand new position + 88 added to an existing one). Only 86 were sellers (61 trimmed + 25 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for TRVI holders?

Strong quality — 32% AUM from major funds: 42 of 215 holders rank in the top 100 by AUM, accounting for 32% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held TRVI?

Mixed — 28% long-term, 35% new: Of the 217 current holders: 61 (28%) held >2 years, 81 held 1–2 years, and 75 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

Is it too late to buy Trevi Therapeutics Inc (TRVI) following the 2026 Q2 hedge fund 13F filings?

As of today, TRVI has moved +0.9% since the 2026 Q2 13F filing date (August 14, 2026), compared to +4.3% for the XLV sector ETF — an outperformance of -3.4%. Since the quarter end (June 30, 2026), TRVI has gained -0.1% vs +10.0% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →